Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.59 |
| ▸ | ACE | P12821 | 9/20 | 0.59 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.53 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.50 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypochlorous Acid SCHEMBL17977228 | 1.00 | MME (0.59) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL20580875 | 0.97 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL8198670 | 0.97 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL1908547 | 0.97 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL8522676 | 0.97 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL2706785 | 0.97 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL2707341 | 0.95 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL4441570 | 0.95 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Bromide SCHEMBL598837 | 0.95 | MME (0.60) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL597864 | 0.95 | MME (0.64) | MMEACEMMEL1GPR88SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| EP-3256444-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | MME, ACE, REN | MME 1/4885ACE 2/4885MMEL1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.